Story perspectives

Everest Medicines to Acquire Hasten for $250M, Expanding Treatment Portfolio

4/9/2026

Summary

Story summary

Everest Medicines plans to acquire Hasten Biopharmaceuticals for US$250 million, gaining rights to 14 chronic-disease treatments in Asia-Pacific.
The deal follows a trend in China’s biopharma activity, with sovereign wealth funds investing in Singapore and UAE.
Cross-border out-licensing by Chinese drugmakers reached a record US$60 billion in early 2026, signaling rising multinational interest.
Syneron Bio, an emerging biotech firm, raised US$150 million for its artificial intelligence (AI)-driven drug development platform.

1 of 1

Story summary

Everest Medicines plans to acquire Hasten Biopharmaceuticals for US$250 million, gaining rights to 14 chronic-disease treatments in Asia-Pacific.
The deal follows a trend in China’s biopharma activity, with sovereign wealth funds investing in Singapore and UAE.
Cross-border out-licensing by Chinese drugmakers reached a record US$60 billion in early 2026, signaling rising multinational interest.
Syneron Bio, an emerging biotech firm, raised US$150 million for its artificial intelligence (AI)-driven drug development platform.